Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Natera
Austin, Texas, United Statesnatera.com ↗
- Ownership
- Public · NTRA
- Employees
- ~2500
- Development stage
- Other
01
Overview
Natera’s cfDNA-based noninvasive tests are highly validated (>300 peer-reviewed publications), widely used in prenatal screening (Panorama), oncology MRD (Signatera), and transplant rejection monitoring (Prospera), with strong clinical validation for early detection and monitoring versus conventional approaches[1][3][4][5][6].
- Therapeutic areas
- OncologyNephrologyRare DiseasesImmunology
- Modalities
- DeviceBioinformatics platform
- Industry
- Molecular Diagnostics
02
Partnerships
Various academic institutions for clinical trials (e.g. CIRCULATE, SMART, Trifecta studies)[3]NRG Oncology for ARCHER bladder cancer study[6]
03
Financials
- Market cap
- $52.4B
- Total revenue
- $2.3B
- Enterprise value
- $51.6B
Beyond the preview
Go deeper on Natera.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Natera.